9:22 AM
Leo Group India
| ||
| /REPEAT -- Cipher Pharmaceuticals announces FDA approval of CIP-ISOTRETINOIN/ MarketWatch (press release) Cipher Pharmaceuticals Inc. (TOR:CA:DND) announced today that the US Food and Drug Administration (FDA) has approved Absorica™, Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant ... See all stories on this topic » | ||
| Ranbaxy gets US OK for acne treatment Reuters India The product was jointly developed by Canadian group Cipher Pharmaceuticals (DND.TO) and Galephar Pharmaceutical Research, while Ranbaxy holds the US marketing rights. Post approval, Cipher will receive a $9 million milestone payment from Ranbaxy, ... See all stories on this topic » | ||
| IDMA-APA Pharmaceutical Analysts' Convention on Sept 21 & 22 in Mumbai pharmabiz.com The Indian Drug Manufacturers' Association (IDMA) and Association of Pharmaceutical Analysts (APA) will be holding the 15th Pharmaceutical Analysts' Convention (PAC) on September 21 and 22, 2012 at Hotel Hyatt Regency, Mumbai. See all stories on this topic » | ||
| Paladin Labs and Nuvo Research Sign Canadian License Agreement for Synera and ... MarketWatch (press release) MONTREAL, QUEBEC AND MISSISSAUGA, ONTARIO, May 28, 2012 (MARKETWIRE via COMTEX) -- May 28, 2012 - Paladin Labs Inc. (TOR:CA:PLB) , a leading specialty pharmaceutical company and Nuvo Research Inc. (TOR:CA:NRI) , a specialty pharmaceutical company ... See all stories on this topic » | ||
| Nuvo Research and Paladin Labs Sign Canadian License Agreement for Synera and ... MarketWatch (press release) MISSISSAUGA, ON and MONTREAL, May 28, 2012 /PRNewswire via COMTEX/ -- Nuvo Research Inc. (TOR:CA:NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune ... See all stories on this topic » | ||
| UBS AG Sets Teva Pharmaceutical Industries Ltd Price Target at $52.00 (TEVA) Daily Political Research analysts at UBS AG (NYSE: UBS) cut their target price on shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) from $60.00 to $52.00 in a report released on Friday. The firm currently has a "buy" rating on the stock. See all stories on this topic » | ||
| Paladin Labs to market Nuvo Research's topical pain medication in Canada Winnipeg Free Press MONTREAL - Speciality pharmaceutical company Paladin Labs Inc. (TSX:PLB) announced Monday that it has been granted the exclusive right to market and sell a new pain medication developed by Nuvo Research Inc. (TSX:NRI). The medication, Synera, is a ... See all stories on this topic » | ||
| Barclays Capital Reaffirms Equal Weight Rating on Teva Pharmaceutical ... Daily Political Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)'s stock had its "equal weight" rating reaffirmed by Barclays Capital (NYSE: BCS) in a research note issued on Friday. A number of other firms have also recently commented on TEVA. See all stories on this topic » | ||
| Needham & Company Gives Hold Rating to Teva Pharmaceutical Industries Ltd (TEVA) Daily Political Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)'s stock had its "hold" rating restated by equities researchers at Needham & Company in a report issued on Friday. Shares of Teva Pharmaceutical Industries Ltd opened at 38.61 on Friday. See all stories on this topic » |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment